Targeted therapies are emerging from increased molecular understanding of neurocutaneous disorders, based on both unique molecular pathways for each syndrome and commonalities among syndromes [i.e., mTOR dysfunction (2, 3, 110)]. The gene discussed is MTOR; the disease is neurocutaneous syndrome.